TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine and Propofol for Upper Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3-13 years~* Receiving general anesthesia for upper endoscopy~Exclusion Criteria:~* Known or possible difficult airway~* BMI \> 35~* Weight \< 10 kg~* Sedative premedication required~* Known contraindication to ketamine or propofol

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine 0 mg/kg (Type: EXPERIMENTAL): Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
- Ketamine 0.25 mg/kg (Type: EXPERIMENTAL): Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
- Ketamine 0.5 mg/kg (Type: EXPERIMENTAL): Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
- Ketamine 1.0 mg/kg (Type: EXPERIMENTAL): Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing Substance Use Through CVCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Both members of the couple:~1. are born male and current male gender identity;~2. identify as gay, bisexual or same-sex attracted;~3. read English at 8th grade level or better;~4. have access to the Internet;~5. agree to audio and video recording of intervention sessions;~At least one member of the couple:~1. reports the use of any drug listed on the DAST-10 in the previous 30 days.~2. s identified as HIV negative during screening and baseline assessments.~   The couple~3. has been together for at least 3 months;~4. has engaged in oral or anal sex with one another in the past 3 months;~Exclusion Criteria:~1. At baseline either member of the couple reports intimate partner violence (IPV), which is defined as serious physical or sexual violence that occurs outside the context of consensual bondage or sado-masochistic sexual play, which results in concerns about safety.~2. At the first in-person meeting, staff will be empowered to deem the couple ineligible for the intervention if they identify inconsistencies between information provided in the eligibility screener and the in-person meeting (e.g., discrepancies in age or duration of relationship) or any issues that might hinder participation (e.g., attending meeting high or drunk). The couple may also be deemed ineligible if participant responses are sufficiently inconsistent to call into question the validity of their individual responses.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CHTC as usual (Type: ACTIVE_COMPARATOR): Participants receive couples HIV testing and counseling following the CDC approved protocol.
- CHTC + communication skills videos (Type: EXPERIMENTAL): The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
- CHTC + substance use module (Type: EXPERIMENTAL): The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
- CHTC + video + substance use module (Type: EXPERIMENTAL): The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infants born at \>36 weeks of gestation and 2 months of age at the time of consent.~* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis).~* Major known congenital malformation or serious chronic disorder.~* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.~* Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 112 Days
- Healthy Volunteers: t

Study Arms:
- 20-valent pneumococcal conjugate vaccine (Type: EXPERIMENTAL): Pneumococcal conjugate vaccine
- 13-valent pneumococcal conjugate vaccine (Type: ACTIVE_COMPARATOR): Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exergame Study for Family Caregivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are caregivers for a family member (e.g., relative, spouse, friend) who is 65 years or older and is either frail, has a disability, or has at least one chronic illness~* 40 years or older~* Own an Android smartphone with Google play store/internet access~* Able to walk for at least 20 minutes at a time~* Comfortable wearing a fitness tracker for the duration of the study~* Familiar with smartphone app usages~* Comfortable with using the study-related app for the duration of the study~Exclusion Criteria:~* Had a recent (within the past 6 months) cardiovascular event or fall.~* Currently participating in any other physical activity study/intervention~* Currently own or use a Fitbit or other activity tracking watches~* Knows someone who is participating or has participated in the study~* Currently physically active (exercise regularly 3 times a week or more for at least 30 minutes)~* More than 2 errors on the Short Portable Mental Status Questionnaire (Pfeiffer, 1975).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Social Exergame Treatment Group (Type: EXPERIMENTAL): The treatment group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the full version of the Go\&Grow fitness app for 6 weeks.
- Control Group (Type: ACTIVE_COMPARATOR): The control group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the Go\&Grow fitness app without the social features for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged 18 years and older~* urologic elective ambulatory procedure. For example:cystoscopy, circumcision,transurethral bladder tumor resection, varicocele and hydrocele surgery~* gynecologic elective ambulatory procedure. For example: hysteroscopy, vulvar ou vaginal biopsy~* general surgery elective ambulatory procedure. For example:inguinal herniorraphy, short ano-rectal procedure~Exclusion Criteria:~* INR \> 1,3~* platelet \< 75 000~* concomitant drugs: clopidogrel (last dose \< 7 days), iv heparin, low molecular weight heparin (last dose \< 24 hours)~* neurologic disease: spinal stenosis, symptomatic lumbar herniated disc, multiple sclerosis~* liquid restriction (cardiac or renal insufficiency)~* allergy or intolerance to chloroprocaine, bupivacaine or PABA~* atypical plasma cholinesterase or deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroprocaine (Type: ACTIVE_COMPARATOR): None
- Bupivacaine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Positive stool sample for rotavirus test~Exclusion Criteria:~* Severe malnourishment~* Severe dehydration~* Use of antibiotics, probiotics or nitazoxanide 2 weeks before admission~* Systemic infections~* Severe chronic disease~* Mixed enteric infections besides rotavirus

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): This group will receive S. Boulardii Probiotic and Oral rehydration as needed
- 2 (Type: ACTIVE_COMPARATOR): This group will receive a mixed Probiotic preparation and oral rehydration as needed
- 3 (Type: PLACEBO_COMPARATOR): This group will receive a placebo, and oral rehydration as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children aged from 6-15 years old as established by medical history and clinical examination~* The subjects' guardians are able to understand and sign the informed consent~* Subjects who can and will comply with the requirements of the protocol~* Subjects with temperature \<=37.0°C on axillary setting before vaccination~Exclusion Criteria:~Exclusion criteria for the first dose~* Subject who has a medical history of stomach illness~* Positive in either serology ELISA test for Helicobacter pylori diagnose kit or 13C urea breath test~* Subject who has suffered from heart, liver, and kidney disease~* Subject who has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine (for example: mannitol)~* Subject who is suffering from thrombocytopenia or other coagulation disorder~* Subject who has a diminished function of the immune system or autoimmune disease~* Subject who is suffering from congenital deformities, developmental disorders or serious chronic diseases~* Family history of seizures or progressive neurological disease~* Severe malnutrition or dysgenopathy, major congenital defects or serious chronic illness, including perinatal brain damage~* Any acute infections in last 7 days~* Any prior administration of immunodepressant or corticosteroids in last 6 month~* Any prior administration of other research medicines in last 1 month~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives~Exclusion criteria for the second and third dose Subjects will not be eligible for the second or third dose if any of following happened after first dose~* Subject who had allergic reaction to the last dose~* Any situation meet the exclusion criteria occurred after the last dose~* Subject who had any serious adverse events related to the vaccination~* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- H. pylori vaccine in children (Type: EXPERIMENTAL): H. pylori vaccine (15mg/dose) in children between 6-15 years of age
- placebo in children (Type: PLACEBO_COMPARATOR): placebo (0mg/dose) in children between 6-15 years of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been diagnosed as ulcerative colitis at least 3 months prior to screening.~* Have active ulcerative colitis despite adequate conventional therapy.~Exclusion Criteria:~* Patients who have severe pancolitis.~* Patients who have undergone surgery for ulcerative colitis within 8 weeks before enrollment or who were judged to require surgery for ulcerative colitis at enrollment.~* Patients who have a history of treatment with infliximab or other biologic products (anti-TNFα agents, anti-IL-6 agents, etc.).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (main):~* Active ulcerative colitis except proctitis, i.e. inflammation minimal 15cm ab ano, confirmed by endoscopy and histology~* Established or new diagnosis~* Disease activity at baseline: Clinical Activity Index (CAI) \>4 and Endoscopic Index (EI) \>= 4~Exclusion Criteria (main):~* Crohn's disease~* Toxic megacolon~* Present or past colorectal cancer~* Symptomatic gastrointestinal disease~* Serious secondary disease(s)~* Baseline stool positive for germs causing bowel disease~* Immunosuppressants within 3 months and/or corticosteroids within 1 month prior to baseline~* Current relapse occurred under maintenance treatment with \>2g/day mesalazine~* Serum creatinine \>= 1.2x upper limit of normal (ULN) and creatinine clearance \< 60 ml/min per 1.73 m2~* Serum transaminase (ALT and/or AST), and/or alkaline phosphatase \>= 2x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Agitated schizophrenic patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of the Infinity Deep Brain Stimulation System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to provide informed consent;~* Subject is diagnosed with Parkinson's disease (PD) and has been recommended to receive an Infinity DBS system with a bilateral DBS implant in the Subthalamic Nucleus (STN), or has received an implant of an Infinity system with bilateral lead implants in the STN;~* Subject must be available for follow-up visits.~Exclusion Criteria:~* Subject is not a surgical candidate;~* In the investigator's opinion, the subject is unable to tolerate multiple programming sessions within a single setting;~* Subject is unable to comply with the follow-up schedule.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omnidirectional followed by directional DBS (Type: None): Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary end point is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.~In this Observational study design, all interventions here are therapeutic interventions that are part of the standard of care, rather than assigned as part of an interventional study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is 1 to 17 years of age~* Able to provide a first-morning urine sample each day during the study~* Documented history of proteinuria associated with chronic kidney disease of any origin~* Signed consent of parent and/or legal guardian~Exclusion Criteria:~* Pregnant and/or nursing~* Requires more than 2 medications to control high blood pressure~* Has undergone major organ transplantation (e.g. heart, kidney, liver)~* Known sensitivity to losartan or other similar drugs, or any history of angioneurotic edema~* Known sensitivity to amlodipine or other calcium channel blocker~* Requires cyclosporine to treat renal disease (kidney disease)

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Losartan Double-Blind Base Study (12-weeks) (Type: EXPERIMENTAL): Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo).
- Amlodipine Double-Blind Base Study (12-weeks) (Type: ACTIVE_COMPARATOR): Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
- Losartan Open-Label Extension Phase (Month 36) (Type: EXPERIMENTAL): Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
- Enalapril Open-Label Extension Phase (Month 36) (Type: ACTIVE_COMPARATOR): Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willingness to participate~* 18 years or older, either gender, any race~* Must have Hepatitic C Virus Low Viral Load \[LCV LVL\] (positive, but \<600,000 IU/mL on the assay used by the individual study site. Only Hepatitis C Virus-Ribonucleic acid/quantitative polymerase chain reaction \[HCV-RNA/qPCR\] assays with results in IU/ml are acceptable) AND been diagnosed with Genotype 1~* Subject considered suitable for treatment per local label~* Investigator considers suitable and subject consents to be treated~Exclusion Criteria:~* Does not show negative polymerase chain reaction \[PCR\] at week 4~* Pregnant women or those who plan to become pregnant or sexual partners of women who plan to become pregnant~* Subject does not qualify based on contra-indication, special warning, special population, and/or pregnancy \& lactation section of the Summary of Product Characteristics \[SmPC\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PegIntron plus Rebetol (Type: None): Those with chronic Hepatitis C infected with HCV LVL G1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete